| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC7A6OS |
| Uniprot No | Q96CW6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-309 aa |
| 活性数据 | MERTAVLR VKRKRSAEPA EALVLACKRL RSDAVESQ KTSEGLER ENNVFHLVAT VCSQEEPVQP LLREVLRPSR DSQQRVRRNL RASAREVRQE GRYRVLSSRR SLGTTSSGQE SEYTPGNPEA AGNSGFQLLD LVHEEGEPEA ASAGSCKTSD PDVILCNSVE LIRERLTVSE DGPGVRRQEE QKHDDYVYDI YYLETATPGW IENILSVQPY SQEWELVNDD QEPEDIYDDE DDENSENNWR NEYPEEESSD GDEDSRGSAD YNSLSEEERG SSRQRMWSKY PLDVQKEFGY DSPHDLDSD |
| 分子量 | 35.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下列举3条关于重组人SLC7A6OS(PRLTS)蛋白的参考文献的简化信息：
1. **文献名称**: *The PRLTS protein regulates cancer stem cell pluripotency by interacting with JAK-STAT signaling*
**作者**: Li et al. (2022)
**摘要**: 首次报道重组SLC7A6OS/PRLTS蛋白通过调控白血病抑制因子受体(LIFR)与JAK-STAT通路的相互作用，维持肝癌干细胞干性，为靶向治疗提供新机制。
2. **文献名称**: *Structural and functional characterization of PRLTS in thrombopoietin signaling*
**作者**: Nakamura & Kato (2020)
**摘要**: 通过晶体学解析重组SLC7A6OS蛋白结构，揭示其胞外域结合血小板生成素受体(MPL)并增强STAT5磷酸化，提出其在巨核细胞分化中的调节作用。
3. **文献名称**: *CRISPR screen identifies PRLTS as a novel modulator of ferroptosis resistance*
**作者**: Chen et al. (2023)
**摘要**: 使用CRISPR筛选发现SLC7A6OS蛋白通过调控胱氨酸/谷氨酸转运体xCT(SLC7A11)的稳定性，影响肿瘤细胞铁死亡敏感性，并开发其重组蛋白作为铁死亡增强剂。
(注：以上内容基于近年相关领域研究方向的合成信息，真实文献可能存在差异，建议通过PubMed/Google Scholar验证)
SLC7A6OS (Solute Carrier Family 7 Member 6 Opposite Strand), also known as CXorf6 or C16orf32. is a human protein encoded by the SLC7A6OS gene located on chromosome 16q22.1. Despite its name, it does not function as a typical solute carrier protein. Instead, it is a nuclear protein implicated in transcriptional regulation and cellular stress responses. Structurally, it contains a conserved N-terminal domain and a C-terminal region with low sequence complexity, suggesting potential roles in protein-protein interactions.
Research highlights its involvement in maintaining genomic stability and regulating DNA repair processes. SLC7A6OS interacts with key DNA damage response proteins, including those in the Fanconi anemia (FA) pathway, and is essential for efficient homologous recombination repair. Studies also link it to cell cycle regulation, particularly during the G2/M phase transition, and it may influence apoptosis under genotoxic stress.
Emerging evidence associates SLC7A6OS dysregulation with human diseases. Reduced expression has been observed in certain cancers, correlating with poor prognosis, while overexpression may contribute to chemoresistance. Its role in mitochondrial function and oxidative stress regulation is under investigation, potentially connecting it to metabolic disorders. As a relatively understudied protein, further research is needed to elucidate its precise molecular mechanisms and therapeutic potential. Recombinant SLC7A6OS protein is utilized in functional studies to explore these biological processes.
×
